| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
LETTER TO THE EDITOR |
Division of Applied Cachexia Research
Department of Cardiology
University Hospital Charité
Campus Virchow-Klinikum
13353 Berlin
Germany
E-mail: anja.sandek{at}charite.de
Dear Sir:
The article by Kalantar-Zadeh et al (1) addresses a very important aspect of current cachexia research, particularly the phenomenon of "reverse epidemiology," by reporting a close relation between a higher and increasing percentage of total body fat and better survival in maintenance hemodialysis (MHD) patients.
This finding adds to a growing body of literature that shows a surprising survival advantage of obese patients in chronic diseases, eg, in chronic heart failure (CHF) and aging, sometimes termed the "obesity paradox" (2, 3). Patients with CHF who lose 6% of their previous weight, thereby meeting the criteria of cachexia, have a particularly poor prognosis (4, 5). Notably, this observation is independent of the patient's high or low baseline body mass index (4). The latter observation supports the view expressed by Kalantar-Zadeh et al, ie, that the advice given to obese patients to lose fat and become catabolic regardless of their limiting underlying disease may not have a solid basis.
Because the 535 patients with end-stage renal disease studied by Kalantar-Zadeh et al are prone to cardiovascular events, the reported survival advantage over the 30-mo follow-up of patients with a percentage body fat of 
24% is even more interesting, particularly if one considers that obesity has been widely viewed as an independent risk factor for cardiovascular diseases. Epidemiologic data for patients with chronic renal failure indicate a 5-y mortality rate of 66%. Cardiovascular events account for 88 deaths per 1000 patient-years at risk and continue to be the single largest cause of mortality (6).
The authors reported 19.8% mortality over a 30-mo follow-up period, which is lower than one would expect (1). Importantly, the precise cause of death was not reported, which could be helpful to highlight the mechanisms behind the "reverse epidemiology." Without this information, the interpretation of a lower mortality rate is not complete and could also reflect a preselected healthier patient population.
Kalantar-Zadeh et al reported the presence of cardiovascular disease in 292 patients, ie, in 54% of their MHD patients. We assume that these patients were treated with a variety of cardiovascular drugs, including angiotensin-converting enzyme (ACE) inhibitors, angiotensin-2-receptor antagonists, ß blockers, and statins for the management of hypertension, coronary artery disease (CAD), and CHF. It is well established that all these drugs improve the prognosis of patients with CAD. Moreover, ß blockers and ACE inhibitors have also been shown to be associated with a survival advantage in patients with end-stage renal failure (7, 8). ACE inhibitors and ß blockers are known to reduce the risk of weight loss (4), and ß blockers inhibit lipolysis and increase body fat—at least in CHF (9). Statins have pleiotropic effects, including the ability to exert antiinflammatory action. This might explain why the authors were unable to show the expected correlation of body fat with increased proinflammatory cytokines (1). Therefore, it would be interesting to see whether the adjustment for medication use would affect the outcome in this study population.
The study by Kalantar-Zadeh et al focused on dynamic changes in body fat mass with the use of near-infrared (NIR) interactance to assess body composition. No data have validated this technique relative to dual-energy X-ray absorptiometry (DXA). The latter method is the gold standard for measuring body fat. NIR measurements are known to underestimate body fat increasingly as the degree of adiposity increases, especially in grossly obese women (10). Therefore, it would be interesting to see whether the reported association of a 1% increase in NIR-measured percentage body fat and a 3% lower mortality risk would be confirmed if DXA analysis is applied.
The authors observed that a decrease in percentage body fat in MHD patients was associated with a death risk 2 times that in patients who had an increase in percentage body fat over 6 mo. Because the authors did not report body weight changes during that period, the question arises whether a decrease in body fat content is paralleled by a shift toward lean mass.
The article by Kalantar-Zadeh et al clearly indicates the need for further basic and clinical studies with more long-term follow up to identify the pathophysiologic mechanisms leading to the increasingly observed obesity advantage in chronic illness and aging. More work is required to validate recommendations for body-composition targets in different chronic disease settings. Potentially, further insight into the underlying mechanisms could change current nutritional advice to patients. Nowadays, both professional and lay public generally regard overweight as a risk factor for morbidity and mortality irrespective of general health status. Future studies will show whether this will hold true for patients with advanced chronic organ failure.
ACKNOWLEDGMENTS
No conflicts of interest were reported.
REFERENCES
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
